MDxHealth proposes 1-for-5 to 1-for-30 reverse split
If approved, the proposed terms would leave share capital unchanged and authorize the board to address fractional positions through aggregation and sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MDxHealth SA has proposed that shareholders approve a reverse stock split of all outstanding shares at a ratio ranging from 1-for-5 to 1-for-30 at an extraordinary meeting on November 19, 2026. If approved, the board would have six months after the meeting to set the final ratio and implement the consolidation. The proposal states that the consolidation would not increase or reduce the company’s share capital.
The meeting requires at least 50% of outstanding shares to be present or represented for the vote; approval requires 75% of votes validly cast. The proposed terms authorize the board to address fractional positions by aggregating and selling shares and distributing proceeds pro rata, with proceeds of at least EUR 0.01 per existing share; proceeds that are lower or cannot be distributed pro rata would accrue to the company.
Filing Explained
Shareholder approval would not guarantee completion: the board could halt implementation under the proposal’s market-conditions clause.
A reverse split reduces the share count and raises the per-share price proportionally, without changing company value; because the proposal applies the same ratio to all outstanding shares, holders' proportional ownership would remain unchanged by the split itself.
The proposal also allows the board not to proceed, or to suspend or cancel implementation already begun, if it determines that market circumstances do not permit completion on terms it considers satisfactory; shareholder approval alone would not guarantee completion.
Key Figures
Key Terms
attendance quorum regulatory
subscription rights financial
pari passu financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What reverse stock split ratio is MDXH proposing?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number 001-40996
MDXHEALTH SA
(Translation of registrant’s name into English)
CAP Business Center
Zone Industrielle des Hauts-Sarts
4040 Herstal, Belgium
+32 4 257 70 21
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
MDXHEALTH SA
MDxHealth SA (the “Company”) hereby furnishes the attached documents in connection with its Extraordinary General Shareholders’ Meeting to be held on Thursday, November 19, 2026 at 4:00 p.m., Belgian time, at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time.
The information in the attached Exhibits 99.1-99.4 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
| Exhibit No. | Description of Exhibit | |
| 99.1 | Convening Notice | |
| 99.2 | Extraordinary General Shareholders’ Meeting Notice Letter | |
| 99.3 | Attendance Form | |
| 99.4 | Proxy Form |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MDXHEALTH SA | |||
| Date: October 30, 2026 | By: | /s/ Michael McGarrity | |
| Name: | Michael McGarrity | ||
| Title: | Chief Executive Officer | ||
2
Exhibit 99.1
Unofficial English translation – For informational purposes only
MDxHealth SA
Limited Liability Company
(société anonyme)
CAP Business Center
Zone Industrielle des Hauts-Sarts
Rue d’Abhooz 31
4040 Herstal, Belgium
VAT BE 0479.292.440 (RLP Liège, division Liège)
INVITATION
extraordinary GENERAL MEETING
to be held on Thursday, November 19, 2026, at 4:00 p.m.
The holders of securities issued by MDxHealth SA (the “Company”) are invited to the extraordinary general shareholders’ meeting of the Company before a notary public.
GENERAL INFORMATION
Date, hour and venue: The extraordinary general shareholders’ meeting will be held on Thursday, November 19, 2026, at 4:00 p.m. at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time. There is an attendance quorum requirement for the item on the agenda of the extraordinary general shareholders’ meeting (see also below under “—Extraordinary general meeting”). If the attendance quorum for the item on the agenda of the extraordinary general shareholders’ meeting were not to be reached, a second extraordinary general shareholders’ meeting will be held for this item on Thursday, December 10, 2026, unless, as the case may be, decided otherwise on behalf of the board of directors.
Opening of the doors: In order to facilitate the keeping of the attendance list on the day of the extraordinary general shareholders’ meeting, holders of securities and their representatives are invited to register as of 3:15 p.m.
extraordinary GENERAL MEETING
Agenda and proposed resolution: The agenda and proposed resolution of the extraordinary general shareholders’ meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the board of directors, are as follows:
| 1. | Share Consolidation (reverse stock split with a ratio ranging between 1-for-5 and 1-for-30) |
Proposed resolution: In accordance with article 7:49 of the Belgian Companies and Associations Code, the extraordinary general shareholders’ meeting decides to effect a share consolidation with respect to all outstanding shares of the Company by means of a reverse stock split with a ratio ranging between 1-for-5 and 1-for-30 (the “Share Consolidation”), and to grant the board of directors of the Company the authority for a six-month period following the date of this extraordinary general shareholders’ meeting to determine the final ratio within such range and further implement the Share Consolidation. If the board of directors does not initiate the process for implementing the Share Consolidation within a six-month period following the date of this extraordinary general shareholders’ meeting, the board of director’s authority to effect the Share Consolidation shall expire, unless renewed. The board of director’s authority to determine the final ratio for the Share Consolidation and to further implement the Share Consolidation is subject to the following terms and conditions:
| (a) | Share Consolidation: All of the outstanding shares of the Company shall be consolidated into a new and reduced number of shares pursuant to a ratio that is to be further determined by the board of directors of the Company prior to the implementation of the Share Consolidation and that must be within a range of one (1) new share for five (5) existing shares and one (1) new share for thirty (30) existing shares (such final ratio as shall be determined by the board of directors, the “Ratio”). Subject to the terms and conditions set out below, the Share Consolidation will be carried out simultaneously for all outstanding shares of the Company in accordance with the Ratio, so that after the completion of the Share Consolidation each new share shall represent the same fraction of the Company’s share capital. The Share Consolidation will not result in a reduction or increase of the Company’s share capital. |
| (b) | Form and nature of the new shares: The Share Consolidation will not affect the form of the outstanding shares (dematerialized or registered) and the outstanding dematerialized and registered shares will be processed separately within the framework of the Share Consolidation. All new shares after the completion of the Share Consolidation shall have the same rights and benefits and shall rank pari passu in all respects, including as to entitlements to dividends and other distributions, in application of the Ratio. |
| (c) | No fractions of new shares: Within the framework of the Share Consolidation, the existing shares can only be consolidated, in accordance with the Ratio as shall be determined by the board of directors, into a whole number of new shares. No fractions of new shares can be issued. Subject to applicable company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall be authorized to determine the manner and process to effect the Share Consolidation with respect to holders of existing shares of the Company who at the time of the Share Consolidation do not have a sufficient number of existing shares in order to receive a whole number of new shares in accordance with the Ratio. Within this context, the board of directors shall have the authority to determine that (i) the positions of old shares that cannot be consolidated into a whole number of new shares in accordance with the Ratio can be aggregated for consolidation into new shares, (ii) such new shares can be sold or placed, via an exempt private placement, block trade, market sale, bookbuilding (accelerated or not) or otherwise, to or with institutional, qualified or professional investors or individuals in and outside of Belgium, and (iii) the proceeds of such sale or placement will be distributed on a pro rata basis to the holders of existing shares that do not have a sufficient number of existing shares to be converted into whole new shares in accordance with the Ratio, provided that the proceeds shall not be less than one euro cent (EUR 0.01) per existing share. If proceeds are less or cannot be distributed on a pro rata basis as aforementioned, these shall accrue to the Company. The relevant transaction costs and expenses (including commissions, fees and expenses of agents and advisors) and applicable taxes, all as applicable, will be borne by the Company. Subject to applicable provisions of company, financial and securities law, the board of directors shall also have the authority to determine that the positions of existing shares that cannot be consolidated in accordance with the Ratio into a whole number of new shares, can be acquired by the Company or one of its subsidiaries and that the proceeds of such sale will be distributed on a pro rata basis as aforementioned. Subject to applicable provisions of company, financial and securities law, the board of directors also has the power to determine, as the case may be and on the basis of objective grounds and practical considerations, that the treatment, timeline and process to deal with fractions of European Shares that cannot be consolidated in accordance with the Ratio into a whole number of new shares shall be different from the treatment, timeline and process in relation to fractions of U.S. Shares that cannot be consolidated in accordance with the Ratio into a whole number of new shares, including in relation to the currency of any payment for European Shares (which shall be in EUR or USD, as shall be determined by the board of directors, taking into account the currency of the proceeds of the aforementioned sale) and for U.S. Shares (which shall be in USD), respectively, provided, however, that the treatment of the European Shares and U.S. Shares, respectively, shall not be manifestly unequal. |
| (d) | Cancellation of existing shares: Following the completion of the Share Consolidation, the existing shares of the Company shall be cancelled and will no longer remain outstanding. |
| (e) | Timing of the Share Consolidation: The board of directors shall be authorized to determine the final Ratio and the effective date of the Share Consolidation, provided however, that the Share Consolidation is to be implemented within a six-month period following the date of this extraordinary general shareholders’ meeting at the latest. The board of directors shall have the authority not to proceed with the implementation of the Share Consolidation, or, in case the implementation of the Share Consolidation has already started, to suspend or cancel the completion of the Share Consolidation if the board of directors determines that the market circumstances do not allow for the completion of the Share Consolidation in circumstances deemed satisfactory to it. |
2
| (f) | Agents: One or more banks or financial institutions shall or may be appointed by the Company for the purpose of the further organization and implementation of the Share Consolidation in relation to the European Shares and U.S. Shares, respectively, including (but not limited to) the consolidation of positions of existing European Shares and U.S. Shares, respectively, that cannot be consolidated into a whole number of new shares in accordance with the Ratio, and the sale of new European Shares and/or U.S. Shares, respectively, as permitted by paragraph (c). |
| (g) | Adjustment of the subscription price of the Subscription Rights: At completion of the Share Consolidation, the Share Consolidation shall be effected in relation to the outstanding subscription rights of the Company in the manner as contemplated in the respective terms and conditions of these subscription rights, so that a holder of subscription rights will have to exercise subscription rights with respect to at least such number of shares prior to the Share Consolidation as shall be required in accordance with the Ratio in order to subscribe for one or more whole shares after the Share Consolidation. |
| (h) | Amendment of the articles of association: At completion of the Share Consolidation, Article 5 of the Company’s articles of association shall be amended and restated to take into account the resulting number of outstanding and existing shares. |
| (i) | Further implementation of the Share Consolidation: Subject to applicable company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall have the authority to further implement and effect the Share Consolidation, including (without being limited to) the authority to (i) determine the final Ratio of the Share Consolidation, (ii) determine the practical implementation of the Share Consolidation (it being understood that a different practical implementation can be determined for the shares that are reflected in the component of the Company’s share register that is held in Belgium and the shares that are reflected directly or indirectly in the component of the Company’s share register that is held in the United States, subject to what is stated in paragraph (c) above), (iii) determine the timing and the effective date of the Share Consolidation as contemplated by paragraph (e), (iv) determine the manner and process to deal with positions of existing European Shares and U.S. Shares, respectively, that cannot be consolidated into a whole number of new shares in accordance with the Ratio as contemplated by paragraph (c), (v) appoint one or more banks or financial institutions for the further organization and implementation of the Share Consolidation as contemplated by paragraph (f), (vi) proceed with the recording of the amendment and the restatement of the articles of association as contemplated by paragraph (h) before a notary public, (vii) take all useful or necessary steps with Nasdaq, Euroclear, Computershare, Depository Trust & Clearing Corporation and any other competent settlement agency, and any regulatory or listing authority in connection with the implementation of the Share Consolidation, (viii) make all changes in the relevant securities register books of the Company reflecting the Share Consolidation, and (ix) do such other things as shall be useful, appropriate or necessary in connection with the foregoing. The board of directors shall have the authority to delegate the further implementation and execution of the Share Consolidation (including the powers referred to in sub-sections (i) to (ix)), in whole or in part, to one or more members of the Company’s executive management or personnel. Any director, any member of the executive management, and any other persons that shall be expressly appointed for such purpose by the board of directors shall be authorized to record the final Ratio of the Share Consolidation and the amendment and the restatement of the articles of association as contemplated by paragraph (h) before a notary public. |
Attendance quorum: According to the Belgian Companies and Associations Code, an attendance quorum of at least 50% of the outstanding shares must be present or represented at the extraordinary general shareholders’ meeting for the deliberation and voting on the item of the aforementioned agenda of the extraordinary general shareholders’ meeting. If such attendance quorum is not reached, a second extraordinary general shareholders’ meeting will be convened for this agenda item, unless, as the case may be, decided otherwise on behalf of the board of directors, and the attendance quorum requirement will not apply to such second meeting.
Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolution referred to in the aforementioned agenda of the extraordinary general shareholders’ meeting shall be passed if it is approved by a majority of 75% of the votes validly cast by the shareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the extraordinary general shareholders’ meeting, but only with an advisory vote.
3
Participation to the meeting
Introduction: Holders of securities issued by the Company who wish to participate to the extraordinary general shareholders’ meeting of the Company should take into account the formalities and procedures described below.
Since the completion, on December 18, 2023, of the Company’s transition from a dual listing of the Company’s former American Depositary Shares on Nasdaq and shares on Euronext Brussels to a sole listing of its shares on Nasdaq, the Company’s shares are comprised of:
| (a) | shares that are reflected in the component of the Company’s share register that is held in Belgium and which is managed by Euroclear Belgium (the “Belgian Share Register” and, the shares reflected in the Belgian Share Register, the “European Shares”), and that cannot be traded on Nasdaq until they have been repositioned into U.S. Shares (as defined below); and |
| (b) | shares that are reflected directly or indirectly in the component of the Company’s share register that is held in the United States and which is managed by Computershare (the “U.S. Share Register” and, the shares reflected in the U.S. Share Register, the “U.S. Shares”), and that can be traded on Nasdaq. |
For further information and details regarding the transition to a single listing on Nasdaq and the repositioning process, please visit the dedicated web page on the Company’s website (see: https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/).
Registration date: In accordance with article 32 of the Company’s articles of association and article 7:134 of the Belgian Companies and Associations Code, the Company’s board of directors sets the registration date for the extraordinary general shareholders’ meeting on Tuesday, November 17, 2026, at midnight (12:00 a.m., Belgian time) (the “Registration Date”). Only persons owning securities issued by the Company on Tuesday, November 17, 2026, at midnight (12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at the extraordinary general shareholders’ meeting. Only shareholders are entitled to vote. The holders of subscription rights can participate to the extraordinary general shareholders’ meeting, but only with an advisory vote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are described under “—Participation to the meeting”.
Participation to the meeting: In order to be able to participate to the extraordinary general shareholders’ meeting, a holder of securities issued by the Company must satisfy two conditions: (a) be registered as holder of such securities on the Registration Date, and (b) notify the Company, as described below:
| (a) | Registration: Firstly, the right for a holder of securities issued by the Company to participate to and, as applicable, to vote at the extraordinary general shareholders’ meeting is only granted on the basis of the registration of the securities concerned on the aforementioned Registration Date at midnight, as follows: |
| (i) | Holders of registered European Shares and registered subscription rights issued by the Company: The holders of registered European Shares and subscription rights in registered form issued by the Company may participate to the extraordinary general shareholders’ meeting only for the registered European Shares and registered subscription rights that are reflected in their name in the Belgian Share Register and relevant register of subscription rights, respectively, on the Registration Date. |
| (ii) | Holders of dematerialised European Shares: The holders of dematerialised European Shares that want participate to the extraordinary general shareholders’ meeting must request their certified account holder or the central securities depositary for the shares concerned to issue a certificate stating the number of dematerialised shares registered in the name of the shareholder in its books on the Registration Date, and to send it to the Company (by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com) at the latest on the business day prior to the extraordinary general shareholders’ meeting, i.e., on or before Wednesday, November 18, 2026, at the latest (the “Notification Deadline”). The Company shall determine the ownership of the relevant shares at the Registration Date solely on the basis of such certificates. |
4
| (iii) | Holders of U.S. Shares, reflected directly in the U.S. Share Register (not through DTCC): The holders of U.S. Shares reflected directly in the U.S. Share Register (not through DTCC) may only be admitted to the extraordinary general shareholders’ meeting if their ownership of U.S. Shares is reflected in the U.S. Share Register on the Registration Date. The Company’s U.S. transfer agent will no later than the Notification Deadline provide the Company directly or indirectly with a shareholder list at the Registration Date that contains all of the registered holders of the Company’s U.S. Shares recorded in the U.S. Share Register directly (not through DTCC) on the Registration Date. The Company shall determine the ownership of the relevant shares at the Registration Date solely on the basis of the aforementioned information. |
| (iv) | Holders of U.S. Shares reflected indirectly in the U.S. Share Register (through DTCC): The holders of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE & Co., the nominee holder of the U.S. Shares held for the beneficial owners through the DTCC system, may only be admitted to the extraordinary general shareholders’ meeting if their ownership of U.S. Shares is included in the information provided to the Company no later than the Notification Deadline through the broker, financial institution or other intermediary of such shareholders. The Company shall determine the ownership of the relevant shares at the Registration Date solely on the basis of the aforementioned information. |
| (b) | Notification: Secondly, in accordance with article 32 of the Company’s articles of association and article 7:134 of the Belgian Companies and Associations Code, the Company’s board of directors sets the deadline for holders of securities issued by the Company to notify their participation to the extraordinary general shareholders’ meeting on the Notification Deadline. Therefore, in order to participate to the extraordinary general shareholders’ meeting, holders of securities issued by the Company must notify the Company whether they want to participate to the meeting, and must do so prior to or at the latest on Wednesday, November 18, 2026. The holders of securities who wish to make such notification can make use of the attendance form that can be obtained at the Company’s registered office and on the Company’s website (http://www.mdxhealth.com). The notice must reach the Company, by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the Notification Deadline. Depending on the type of securities it holds, a holder of securities issued by the Company must notify to the Company its participation to the extraordinary general shareholders’ meeting as follows: |
| (i) | Holders of registered European Shares and registered subscription rights issued by the Company: Holders of registered European Shares and subscription rights in registered form issued by the Company that wish to make such notification must make sure that the attendance form is duly signed and completed and reaches the Company no later than the Notification Deadline (pursuant to the instructions set out above). |
| (ii) | Holders of dematerialised European Shares: Holders of dematerialised European Shares that wish to make such notification must make sure that the attendance form is duly signed and completed and reaches the Company no later than the Notification Deadline (pursuant to the instructions set out above). Furthermore, the notification must include a certificate confirming the number of European Shares that have been registered in their name on the Registration Date. The certificate can be obtained by the holders of the dematerialised European Shares with the certified account holder or the central securities depositary for the European Shares concerned (see also under (ii) in paragraph (a) above). |
| (iii) | Holders of U.S. Shares, reflected directly in the U.S. Share Register (not through DTCC): Holders of U.S. Shares reflected directly in the U.S. Share Register (not through DTCC) that wish to make such notification must make sure that the attendance form included as part of their notice is duly completed and reaches the Company no later than the Notification Deadline (pursuant to the instructions set out above). |
5
| (iv) | Holders of U.S. Shares reflected indirectly in the U.S. Share Register (through DTCC): Holders of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE & Co., the nominee holder of the U.S. Shares held for the beneficial owners through the DTCC system, that wish to make such notification must make sure that the attendance form is duly completed and reaches the Company no later than the Notification Deadline (pursuant to the instructions set out above). Furthermore, the notification must include a certificate from a broker, financial institution or other intermediary indicating that such holder was the owner of such U.S. Shares on the Registration Date. |
The Company encourages shareholders to participate to the extraordinary general shareholders’ meeting through a signed proxy or the U.S. proxy card (as further explained below under “—Representation by proxy”) that will be provided or is made available to them and in accordance with the accompanying instructions. If a shareholder attends to the extraordinary general shareholders’ meeting in person, it may revoke its signed proxy or U.S. proxy card until the Notification Deadline. Providing to the Company a signed proxy or U.S. proxy card to the Company shall also qualify as a notification, provided that the signed proxy or U.S. proxy card reaches the Company (by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com) no later than the Notification Deadline. For the shareholders referred to in (ii) and (iv) above, the signed proxy or U.S. proxy card must also include the certificates referred to in (ii) and (iv) above respectively.
Representation by proxy: The holders of securities can participate to the meeting and vote, as applicable, through a written proxy. Written proxies must contain specific voting instructions for the proposed resolution. Proxy forms can be obtained on the Company’s website (http://www.mdxhealth.com). The proxy form must be signed in writing or electronically. Holders of U.S Shares who want to appoint a proxy are strongly encouraged to use the U.S. proxy card that will be provided to them and according to the accompanying instructions. Signed proxies and U.S. proxy cards must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the Notification Deadline, i.e., on or before Wednesday, November 18, 2026 at the latest. Holders of securities who wish to be represented by proxy must, in any case comply with the formalities to participate to the meeting, as explained under “—Participation to the meeting”. For the shareholders referred to in (ii) and (iv) of paragraph (b) of “—Participation to the meeting”, the signed proxy or U.S. proxy card must also include the certificates referred to in (ii) and (iv), respectively, of paragraph (b) of “—Participation to the meeting”.
Access to the meeting room: The natural persons who attend to the extraordinary general shareholders’ meeting in their capacity as owner of securities, holder of proxies or representative of a legal entity must be able to provide evidence of their identity in order to be granted access to the meeting room (subject to what is shared above under “—General information”). In addition, the representatives of legal entities must hand over the documents establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start of the meeting.
Recommendation to use e-mail: The Company recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders’ meeting. The Company’s e-mail address for such communication is: agsm@mdxhealth.com. The Company also points at that, in addition to be physically available at the Company’s registered office and distributed by mail, all forms and other documentation in relation to the general shareholders’ meeting will be available on the Company’s website (http://www.mdxhealth.com). See also “—Available documentation”.
6
Data Protection
The Company is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and proxy holders in the context of general shareholders’ meeting. The processing of such data will be carried out for the purposes of the organisation and conduct of the relevant general shareholders’ meeting, including the convening notices, registrations, participation and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or services to the Company in connection with the foregoing. The processing of such data will be carried out, mutatis mutandis, in accordance with the Company’s Privacy Policy, available on the Company’s website (https://mdxhealth.com/privacy-policy). The Company draws the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in the aforementioned Privacy Policy. All this does not affect the rules that apply in connection with the registration and participation to the general shareholders’ meeting. To exercise rights as a data subject and for all other information regarding the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@mdxhealth.com.
available documentation
The following documentation is available on the Company’s website (http://www.mdxhealth.com): the notice convening the extraordinary general shareholders’ meeting, the documents to be submitted to the extraordinary general shareholders’ meeting as referred to in the agenda of the meeting, the attendance form, and the proxy form. Prior to the extraordinary general shareholders’ meeting, holders of securities of the Company can also obtain at the registered office of the Company (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium), free of cost, a copy of this documentation.
Please address any correspondence on this matter to MDxHealth SA, Mr. Ron Kalfus CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium. The e-mail address is agsm@mdxhealth.com.
On behalf of the board of directors
This document is not an offer to sell or a solicitation of an offer to buy shares or other securities of mdxhealth sa.
7
Exhibit 99.2
| MDxHealth SA | |
| CAP Business Center | |
| Rue d’Abhooz, 31 | |
| B-4040 Herstal - Belgium | |
| E. info@mdxhealth.com | |
| www.mdxhealth.com |
October 30, 2026
Dear Shareholder,
| Re: | Extraordinary general shareholders’ meeting of MDxHealth SA to be held on November 19, 2026 |
On behalf of the Board of Directors of MDxHealth SA (the “Company”), you are cordially invited to attend the extraordinary general shareholders’ meeting (“Extraordinary Meeting”) to be held in-person on Thursday, November 19, 2026, at 4:00 p.m. (Belgian time) at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium.
The agenda, proposed resolution and the other documents for the Extraordinary Meeting are available in French and English on the Company’s website (see: https://www.mdxhealth.com/shareholder-information/). We encourage you to read these materials carefully.
Whether or not you plan to attend the meeting, your vote is important, and we encourage you to vote promptly.
For a description of the formalities to be fulfilled by holders of securities of the Company to participate and vote in an Extraordinary Meeting, please see the notice convening the meeting, which can be found on the Company’s website.
You may also vote your shares through one of the methods described in the accompanying proxy card.
| Sincerely, | |
| /s/ Michael K McGarrity | |
| Michael K. McGarrity | |
| CEO & Director |
TVA BE 0479.292.440 RPM (Liège) ● KBC Bank 736-0304341-19
NOTICE OF MDXHEALTH SA
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
NOVEMBER 19, 2026 4:00 P.M. (Belgian Time)
At the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium
To the Shareholders of MDxHealth SA:
The extraordinary general shareholders’ meeting (“Extraordinary Meeting”) is to be held in-person on Thursday, November 19, 2026, at 4:00 p.m. Central European Time at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium.
The purpose of the Extraordinary Meeting is to report on and approve:
| 1. | Share Consolidation (reverse stock-split with a ratio ranging between 1-for-5 and 1-for-30) |
The detailed agenda, proposed resolution and the other documents for the Extraordinary Meeting are available in French and English on the Company’s website (see: https://www.mdxhealth.com/shareholder-information/). We encourage you to read these materials carefully.
YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, PLEASE VOTE YOUR SHARES IN ACCORDANCE WITH THE INSTRUCTIONS SET OUT ON THE ACCOMPANYING PROXY CARD. PROXY CARDS SHOULD BE DATED, SIGNED AND RETURNED FOR RECEIPT BY OR BEFORE NOVEMBER 16, 2026. YOUR PROMPT COOPERATION IS GREATLY APPRECIATED.
| On behalf of the board of directors | |
| /s/ Joseph Sollee | |
| Joseph Sollee | |
| General Counsel & Secretary of the Board of Directors |
TVA BE 0479.292.440 RPM (Liège) ● KBC Bank 736-0304341-19
Exhibit 99.3
MDxHealth SA
Limited Liability Company
(société anonyme)
CAP Business Center
Zone Industrielle des Hauts-Sarts
Rue d’Abhooz 31
4040 Herstal, Belgium
VAT BE 0479.292.440 (RLP Liège, division Liège)
| ATTENDANCE FORM
FOR SECURITY HOLDERS Extraordinary General Meeting to be held on Thursday, November 19, 2026, at 4:00 p.m. (Belgian time) |
|
This attendance form should be used by holders of securities of MDxHealth SA (the “Company”) who want to attend the extraordinary general shareholders’ meeting in person. More information regarding the requirements for, and the modalities of, participation in the meeting can be found in the convening notice of the extraordinary general shareholders’ meeting.
The signed and completed form must reach the Company at the latest on the business day prior to the extraordinary general shareholders’ meeting, i.e., on or before Wednesday, November 18, 2026 at the latest, by mail to:
MDxHealth SA or by e-mail to: agsm@mdxhealth.com
The use of e-mail is strongly encouraged.
The Company’s shares are comprised of: (a) shares that are reflected in the component of the Company’s share register that is held in Belgium and which is managed by Euroclear Belgium (the “Belgian Share Register” and, the shares reflected in the Belgian Share Register, the “European Shares”), and that cannot be traded on Nasdaq until they have been repositioned into U.S. Shares (as defined below), and (b) shares that are reflected directly or indirectly in the component of the Company’s share register that is held in the United States and which is managed by Computershare (the “U.S. Share Register” and, the shares reflected in the U.S. Share Register, the “U.S. Shares”), and that can be traded on Nasdaq.
Holders of dematerialised European Shares must attach to the present form a certificate issued by the certified account holder or the central securities depositary for the shares concerned, confirming the number of dematerialised European Shares that have been registered in their name on the registration date (i.e., Tuesday, November 17, 2026, at midnight (12:00 a.m., Belgian time)) (the “Registration Date”), with which they want to participate to the extraordinary general shareholders’ meeting.
Holders of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE & Co., the nominee holder of the U.S. Shares held for the beneficial owners through the DTCC system, must attach to the present form a certificate from a broker, financial institution or other intermediary confirming their ownership of U.S. Shares on the Registration Date, with which they want to participate to the extraordinary general shareholders’ meeting. |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Attendance form for security holders |
The undersigned,
| First Name: | ||
| Family Name: | ||
| Address: | ||
| or | ||
| Corporate name: | ||
| Corporate form: | ||
| Registered office: | ||
| Represented by (first name, family name and capacity): | ||
owner of the following number of securities issued by MDxHealth SA, with registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium:
| (1) dematerialised European Shares | ||
| (1) U.S. Shares reflected directly in the U.S. | ||
| Share Register (not through DTCC) | ||
| (1) U.S. Shares reflected indirectly in the U.S. | ||
| Share Register (through DTCC) | ||
| (1) subscription rights (2) | ||
| Notes: | ||
| (1) | Number of relevant securities to be completed, when applicable. | |
| (2) | Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders’ meeting, but only with an advisory vote. | |
Hereby notifies his/her/its intent to attend the extraordinary general shareholders’ meeting of MDxHealth SA to be held on Thursday, November 19, 2026, at 4:00 p.m. (Belgian time) at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place indicated at that place at that time.
The undersigned agrees that the English translation of the present attendance form is a free translation and for information purposes only, and that the French version shall prevail over the English translation.
The undersigned hereby confirms that the Company can send all confirmations and information required for participation in the extraordinary general shareholders’ meeting to the following e-mail address of the undersigned:
| (E-mail address of security holder) | ||
Done at ______________________, on ______________________2026
Signature ______________________
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Attendance form for security holders |
Exhibit 99.4
| AssemblÉe
gÉnÉrale extraordinaire des Actionnaires 19 Novembre 2026 |
extraordinary
general shareholders’ meeting november 19, 2026 |
| Procuration | Proxy |
Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial à l’assemblée générale extraordinaire des actionnaires de la Société à tenir le jeudi 19 novembre 2026 à 16h00 (heure belge). Nonobstant ce qui précède, les titulaires d’Actions Américaines (telles que définies ci-dessous) qui souhaitent désigner un mandataire sont vivement encouragés à utiliser la carte de procuration américaine (U.S. proxy card) qui leur a été fournie et à suivre les instructions qui l’accompagnent. |
This proxy should be used by holders of securities of MDxHealth SA (the “Company”) who want to be represented by a proxy holder at the extraordinary general shareholders’ meeting of the Company to be held on Thursday, November 19, 2026, at 4:00 p.m. (Belgian time). Notwithstanding the above, holders of U.S. Shares (as defined below) who want to appoint a proxy are strongly encouraged to use the U.S. proxy card provided to them and according to the accompanying instructions. |
Les actions de la Société se composent : (a) d’actions inscrites dans la composante du registre des actions de la Société qui est tenue en Belgique et qui est maintenue par Euroclear Belgium (le “Registre Belge des Actions” et, les actions reflétées dans le Registre Belge des Actions, les “Actions Européennes”), et qui ne peuvent pas être négociées sur le Nasdaq tant qu’elles n’ont pas été repositionnées en Actions Américaines (telles que définies ci-dessous), et (b) d’actions inscrites directement ou indirectement dans la composante du registre des actions de la Société tenue aux États-Unis et qui est maintenue par Computershare (le “Registre Américain des Actions” et, les actions figurant dans le Registre Américain des Actions, les “Actions Américaines”), et qui peuvent être négociées sur le Nasdaq. |
The Company’s shares are comprised of: (a) shares that are reflected in the component of the Company’s share register that is held in Belgium and which is managed by Euroclear Belgium (the “Belgian Share Register” and, the shares reflected in the Belgian Share Register, the “European Shares”), and that cannot be traded on Nasdaq until they have been repositioned into U.S. Shares (as defined below), and (b) shares that are reflected directly or indirectly in the component of the Company’s share register that is held in the United States and which is managed by Computershare (the “U.S. Share Register” and, the shares reflected in the U.S. Share Register, the “U.S. Shares”), and that can be traded on Nasdaq. |
Cette procuration ne constitue pas une sollicitation publique de procuration au sens des article 7:145 du Code des sociétés et des associations. |
This proxy does not constitute a proxy solicitation in the sense of article 7:145 of the Belgian Companies and Associations Code. |
La procuration doit être signée de façon écrite ou électroniquement. |
The proxy must be signed in writing or electronically. |
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 1/10 |
La procuration signée et complétée doit parvenir à la Société au plus tard le jour ouvrable qui précède l’assemblée générale extraordinaire des actionnaires, soit le, ou avant le, mercredi 18 novembre 2026 (la “Date limite de Notification”) au plus tard. Jusqu’à cette date, les procurations peuvent être envoyées à l’adresse suivante : |
The signed and completed proxy must reach the Company at the latest on the business day prior to the extraordinary general shareholders’ meeting, i.e. on or before Wednesday, November 18, 2026 (the “Notification Deadline”) at the latest. Until the Notification Deadline, proxies can be sent to the following address: |
|
MDxHealth SA Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31, |
MDxHealth SA CAP Business Center Zone Industrielle des Hauts-Sarts |
ou par courrier électronique à : |
or by e-mail to: |
agsm@mdxhealth.com |
agsm@mdxhealth.com |
Les titulaires de titres de la Société qui désirent être représentés par procuration doivent aussi s’enregistrer à l’assemblée générale extraordinaire des actionnaires, tel que décrit dans l’invitation à l’assemblée générale extraordinaire des actionnaires. Les titulaires d’Actions Européennes dématérialisées doivent joindre à ce formulaire un certificat délivré par le teneur de compte agréé ou le dépositaire central de titres pour les actions concernées, confirmant le nombre d’Actions Européennes dématérialisées ayant été enregistrées à leur nom à la date d’enregistrement (soit le mardi 17 novembre 2026, à minuit (00h00, heure belge)) (la “Date d’Enregistrement”) et avec lesquelles ils veulent participer à l’assemblée générale extraordinaire des actionnaires. Les titulaires d’Actions Américaines inscrites indirectement dans le Registre Américain des Actions, par l’intermédiaire de CEDE & Co, le détenteur désigné des Actions Américaines détenues pour les bénéficiaires effectifs via le système DTCC, doivent joindre au présent formulaire un certificat d’un courtier, d’une institution financière ou d’un autre intermédiaire confirmant leur propriété des Actions Américaines à la Date d’Enregistrement, avec lesquelles ils souhaitent participer à l’assemblée générale extraordinaire des actionnaires. |
Holders of securities of the Company who wish to be represented by proxy must also register for the extraordinary general shareholders’ meeting, as described in the notice convening the extraordinary general shareholders’ meeting. Holders of dematerialised European Shares must attach to the present form a certificate issued by the certified account holder or the central securities depositary for the shares concerned, confirming the number of dematerialised European Shares that have been registered in their name on the registration date (i.e., Tuesday, 17 November 2026, at midnight (12:00 a.m., Belgian time)) (the “Registration Date”), with which they want to participate to the extraordinary general shareholders’ meeting. Holders of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE & Co., the nominee holder of the U.S. Shares held for the beneficial owners through the DTCC system, must attach to the present form a certificate from a broker, financial institution or other intermediary confirming their ownership of U.S. Shares on the Registration Date, with which they want to participate to the extraordinary general shareholders’ meeting. |
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 2/10 |
La Société recommande d’utiliser le courrier électronique pour toute communication avec la Société concernant l’assemblée générale des actionnaires. |
The Company recommends to use e-mail for all communication with the Company regarding the general shareholders’ meeting. |
| Le/La soussigné(e), | The undersigned, |
| Prénom / First name: | ||
| Nom de famille / Family name: | ||
| Adresse / Address: | ||
| ou / or | ||
| Dénomination / Corporate name: | ||
| Forme juridique / Corporate form: | ||
| Siège / Registered office: | ||
| Représenté par (prénom, nom de famille et | ||
| qualité) / Represented by (first name, family name and capacity): | ||
titulaire du (des) nombre(s) suivant(s) de titres émis par MDxHealth SA, ayant son siège au CAP Business Center, Zone Industrielle des Hauts-Sarts, Rue d’Abhooz 31, 4040 Herstal, Belgique, |
owner of the following number of securities issued by MDxHealth SA, with its registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, |
| Nombre d’Actions Européennes nominatives / Number of registered European Shares: | |||
| Nombre d’Actions Européennes dématérialisées / Number of dematerialised European Shares: | |||
| Nombre d’Actions Américaines, inscrites directement dans le Registre Américain des Actions (pas par l’intermédiaire de DTCC) / Number of U.S. Shares reflected directly in the U.S. Share Register (not through DTCC): | |||
| Nombre d’Actions Américaines, inscrites indirectement dans le Registre Américain des Actions (par l’intermédiaire de DTCC) / Number of U.S. Shares reflected indirectly in the U.S. Share Register (through DTCC): | |||
| Nombre de droits de souscription / Number of subscription rights:1 |
constitue pour mandataire spécial, avec pouvoir de substitution: |
appoints as his/her/its proxy holder, with power of substitution: |
| ☐ M./Mme / Mr./Ms. | 2 | |
| ☐ Président du conseil d’administration / Chair of the board of directors3 | ||
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 3/10 |
| 1 Conformément à l’article 7:135 du Code des sociétés et des associations, les titulaires de droits de souscription ont le droit de participer à l’assemblée générale des actionnaires mais seulement avec voix consultative. | 1 Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders’ meeting, but only with an advisory vote. |
| 2 Veuillez compléter tel qu’approprié. Une absence d’instruction sera interprétée comme une nomination du président du conseil d’administration en tant que mandataire. | 2 Please complete as appropriate. An absence of instruction shall be tantamount to an appointment of the chair of the board of directors as proxy holder. |
| 3 Le président du conseil d’administration de la Société a le pouvoir de nommer un autre administrateur, un employé ou remplaçant désigné de la Société comme suppléant en vertu d’une sous-délégation si le président est empêché d’assister à l’assemblée générale des actionnaires. Le président ou son suppléant ne vote qu’en exécution de la procuration, conformément aux instructions de vote spécifiques figurant dans la procuration. Voir également la note 4 ci-dessous. | 3 The chair of the board of directors of the Company has the power to appoint another director, employee or substitute of the Company as a substitute pursuant to a sub delegation if the chair is hindered to attend the general shareholders’ meeting. The chair or his substitute may only vote in execution of the proxy, in accordance with the specific voting instructions included in the proxy. See also note 4 below. |
| lequel accepte ainsi d’être nommé, et à qui le/la soussigné(e) donne les pouvoirs et instructions de vote spécifiques suivants:4 | who agrees to be so appointed, and to whom the undersigned gives the following powers and specific voting instructions:4 |
| 4 Veuillez indiquer l’instruction de vote dans la case appropriée pour le point à l’ordre du jour. En l’absence d’une instruction de vote pour le point de l’ordre du jour, ou dans le cas où, pour quelque raison que ce soit, il y aurait un manque de clarté concernant les instructions de vote, le mandataire sera présumé avoir voté “Pour” la résolution proposée soutenue par le conseil d’administration et cela sera considéré comme une instruction de vote spécifique au sens de l’article 7:143 §4 2° du Code des sociétés et des associations. | 4 Please indicate the voting instructions in the appropriate box of the agenda item. In the absence of voting instructions for the agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards to the voting instructions, the proxy holder will be presumed to have voted “For” the proposed resolution supported by the board of directors and that this will be deemed to be a specific voting instruction in the sense of article 7:143 §4 2° of the Belgian Companies and Associations Code. |
| I. De représenter le/la soussigné(e) à l’assemblée générale extraordinaire des actionnaires à tenir le jeudi 19 novembre 2026 à 16h00 (heure belge), dans les bureaux de Maître Stijn Raes, notaire, à Kortrijksesteenweg 1147, 9051 Gand, Belgique, ou à tout autre endroit qui sera indiqué à cette occasion. | I. To represent the undersigned at the extraordinary general meeting of shareholders to be held on Thursday, 19 November 2026, at 4:00 p.m. (Belgian time), at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such place as will be indicated at that place at that time. |
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 4/10 |
| ORDRE DU JOUR assemblée générale extraordinaire |
agenda extraordinary general meeting | ||||
| 1. | Regroupement d’Actions (sur la base d’un ratio compris entre 1 pour 5 et 1 pour 30) | 1. | Share Consolidation (reverse stock split with a ratio ranging between 1-for-5 and 1-for-30) | ||
| ► Proposition de résolution : | ► Proposed resolution: | ||||
| Conformément à l’article 7:49 du Code des sociétés et des associations, l’assemblée générale extraordinaire des actionnaires décide d’effectuer un regroupement d’actions concernant toutes les actions en circulation de la Société au moyen d’un regroupement d’actions sur la base d’un ratio compris entre 1 pour 5 et 1 pour 30 (le “Regroupement d’Actions”), et d’accorder au conseil d’administration de la Société, pour une période de six mois suivant la date de cette assemblée générale extraordinaire des actionnaires, le pouvoir de déterminer le ratio définitif dans cette fourchette et l’autorisation de poursuivre la mise en œuvre du Regroupement d’Actions. Si le conseil d’administration n’entame pas la procédure de mise en œuvre du Regroupement d’Actions dans un délai de six mois à compter de la date de la présente assemblée générale extraordinaire des actionnaires, le pouvoir du conseil d’administration d’effectuer le Regroupement d’Actions expirera, à moins qu’il ne soit renouvelé. Le pouvoir du conseil d’administration de déterminer le ratio définitif du Regroupement d’Actions et de mettre en œuvre le Regroupement d’Actions est soumis aux conditions suivantes : | In accordance with article 7:49 of the Belgian Companies and Associations Code, the extraordinary general shareholders’ meeting decides to effect a share consolidation with respect to all outstanding shares of the Company by means of a reverse stock split with a ratio ranging between 1-for-5 and 1-for-30 (the “Share Consolidation”), and to grant the board of directors of the Company the authority for a six-month period following the date of this extraordinary general shareholders’ meeting to determine the final ratio within such range and further implement the Share Consolidation. If the board of directors does not initiate the process for implementing the Share Consolidation within a six-month period following the date of this extraordinary general shareholders’ meeting, the board of director’s authority to effect the Share Consolidation shall expire, unless renewed. The board of director’s authority to determine the final ratio for the Share Consolidation and to further implement the Share Consolidation is subject to the following terms and conditions: | ||||
| (a) Regroupement d’Actions : Toutes les actions en circulation de la Société seront regroupées en un nombre nouveau et réduit d’actions selon un ratio qui sera déterminé ultérieurement par le conseil d’administration de la Société avant la mise en œuvre du Regroupement d’Actions et qui devra être compris entre une (1) nouvelle action pour cinq (5) actions existantes et une (1) nouvelle action pour trente (30) actions existantes (ce ratio définitif, tel que déterminé par le conseil d’administration, étant le “Ratio”). Sous réserve des conditions énoncées ci-dessous, le Regroupement d’Actions sera effectué simultanément pour toutes les actions en circulation de la Société conformément au Ratio, de sorte qu’après l’achèvement du processus de Regroupement d’Actions, chaque nouvelle action représentera la même fraction du capital de la Société. Le Regroupement d’Actions n’entraînera pas de réduction ou d’augmentation du capital de la Société: | (a) Share Consolidation: All of the outstanding shares of the Company shall be consolidated into a new and reduced number of shares pursuant to a ratio that is to be further determined by the board of directors of the Company prior to the implementation of the Share Consolidation and that must be within a range of one (1) new share for five (5) existing shares and one (1) new share for thirty (30) existing shares (such final ratio as shall be determined by the board of directors, the “Ratio”). Subject to the terms and conditions set out below, the Share Consolidation will be carried out simultaneously for all outstanding shares of the Company in accordance with the Ratio, so that after the completion of the Share Consolidation each new share shall represent the same fraction of the Company’s share capital. The Share Consolidation will not result in a reduction or increase of the Company’s share capital. | ||||
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 5/10 |
| (b) | Forme et nature des nouvelles actions : Le Regroupement d’Actions n’affectera pas la forme des actions en circulation (dématérialisées ou nominatives) et les actions dématérialisées et nominatives en circulation seront traitées séparément dans le cadre du Regroupement d’Actions. Toutes les nouvelles actions après l’achèvement du processus de Regroupement d’Actions seront assorties des mêmes droits et avantages et seront pari passu à tous égards, y compris en ce qui concerne les droits aux dividendes et autres distributions, en application du Ratio. | (b) | Form and nature of the new shares: The Share Consolidation will not affect the form of the outstanding shares (dematerialized or registered) and the outstanding dematerialized and registered shares will be processed separately within the framework of the Share Consolidation. All new shares after the completion of the Share Consolidation shall have the same rights and benefits and shall rank pari passu in all respects, including as to entitlements to dividends and other distributions, in application of the Ratio. | ||
| (c) | Pas de fractions de nouvelles actions : Dans le cadre du Regroupement d’Actions, les actions existantes ne peuvent être regroupées, conformément au Ratio tel que déterminé par le conseil d’administration, qu’en un nombre entier de nouvelles actions. Aucune fraction de nouvelles actions ne peut être émise. Sous réserve des règles applicables en matière de droit des sociétés, de droit financier et de droit des valeurs mobilières, et sous réserve des dispositions des paragraphes précédents, le conseil d’administration est autorisé à déterminer la manière et la procédure à suivre pour effectuer le Regroupement d’Actions à l’égard des détenteurs d’actions existantes de la Société qui, au moment du Regroupement d’Actions, ne disposent pas d’un nombre suffisant d’actions existantes pour recevoir un nombre entier de nouvelles actions conformément au Ratio. Dans ce contexte, le conseil d’administration aura le pouvoir de déterminer que (i) les positions des anciennes actions qui ne peuvent pas être regroupées en un nombre entier de nouvelles actions conformément au Ratio peuvent être agrégées pour être regroupées en nouvelles actions, (ii) ces nouvelles actions peuvent être vendues ou placées, par le biais d’un placement privé exempté, d’une vente en bloc de titres, d’une vente sur le marché, d’une procédure (accéléré ou non) de constitution d’un livre d’ordres ou autrement, à ou auprès d’investisseurs institutionnels, qualifiés ou professionnels ou de particuliers en Belgique et ailleurs, et (iii) le produit de cette vente ou de ce placement sera distribué au prorata aux détenteurs d’actions existantes qui n’ont pas un nombre suffisant d’actions existantes pour être converties en nouvelles actions entières conformément au Ratio, à condition que le produit ne soit pas inférieur à un centime d’euro (EUR 0,01) par action existante. Si le produit est inférieur ou ne peut être distribué au prorata comme indiqué ci-dessus, il sera distribué à la Société. Les coûts et frais de transaction pertinents (y compris les commissions, honoraires et frais des agents et conseillers) et les taxes, le tout tel qu’applicable, seront supportés par la Société. Sous réserve des dispositions applicables de droit des sociétés, de droit financier et de droit des valeurs mobilières, le conseil d’administration a également le pouvoir de décider que les positions des actions existantes qui ne peuvent être regroupées conformément au Ratio en un nombre entier de nouvelles actions peuvent être acquises par la Société ou l’une de ses filiales et que le produit de cette vente sera distribué au prorata comme indiqué ci-dessus. Sous réserve des dispositions applicables du droit des sociétés, du droit financier et du droit des marchés financiers, le conseil d’administration a également le pouvoir de déterminer, le cas échéant et sur la base de critères objectifs et de considérations pratiques, que le traitement, le calendrier et la procédure applicables aux fractions d’Actions Européennes qui ne peuvent être regroupées, conformément au Ratio, en un nombre entier de nouvelles actions, seront différents du traitement, du calendrier et de la procédure applicables aux fractions d’Actions Américaines qui ne peuvent être regroupées, conformément au Ratio, en un nombre entier de nouvelles actions, notamment en ce qui concerne la devise de tout paiement relatif aux Actions Européennes (qui sera effectuée en EUR ou en USD, selon ce que déterminera le conseil d’administration, compte tenu de la devise du produit de la vente susmentionnée) et aux Actions Américaines (qui sera effectuée en USD), étant toutefois entendu que le traitement des Actions Européennes et des Actions Américaines ne pourra pas être manifestement inégal. | (c) | No fractions of new shares: Within the framework of the Share Consolidation, the existing shares can only be consolidated, in accordance with the Ratio as shall be determined by the board of directors, into a whole number of new shares. No fractions of new shares can be issued. Subject to applicable company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall be authorized to determine the manner and process to effect the Share Consolidation with respect to holders of existing shares of the Company who at the time of the Share Consolidation do not have a sufficient number of existing shares in order to receive a whole number of new shares in accordance with the Ratio. Within this context, the board of directors shall have the authority to determine that (i) the positions of old shares that cannot be consolidated into a whole number of new shares in accordance with the Ratio can be aggregated for consolidation into new shares, (ii) such new shares can be sold or placed, via an exempt private placement, block trade, market sale, bookbuilding (accelerated or not) or otherwise, to or with institutional, qualified or professional investors or individuals in and outside of Belgium, and (iii) the proceeds of such sale or placement will be distributed on a pro rata basis to the holders of existing shares that do not have a sufficient number of existing shares to be converted into whole new shares in accordance with the Ratio, provided that the proceeds shall not be less than one euro cent (EUR 0.01) per existing share. If proceeds are less or cannot be distributed on a pro rata basis as aforementioned, these shall accrue to the Company. The relevant transaction costs and expenses (including commissions, fees and expenses of agents and advisors) and applicable taxes, all as applicable, will be borne by the Company. Subject to applicable provisions of company, financial and securities law, the board of directors shall also have the authority to determine that the positions of existing shares that cannot be consolidated in accordance with the Ratio into a whole number of new shares, can be acquired by the Company or one of its subsidiaries and that the proceeds of such sale will be distributed on a pro rata basis as aforementioned. Subject to applicable provisions of company, financial and securities law, the board of directors also has the power to determine, as the case may be and on the basis of objective grounds and practical considerations, that the treatment, timeline and process to deal with fractions of European Shares that cannot be consolidated in accordance with the Ratio into a whole number of new shares shall be different from the treatment, timeline and process in relation to fractions of U.S. Shares that cannot be consolidated in accordance with the Ratio into a whole number of new shares, including in relation to the currency of any payment for European Shares (which shall be in EUR or USD, as shall be determined by the board of directors, taking into account the currency of the proceeds of the aforementioned sale) and for U.S. Shares (which shall be in USD), respectively, provided, however, that the treatment of the European Shares and U.S. Shares, respectively, shall not be manifestly unequal. |
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 6/10 |
| (d) | Annulation des actions existantes : Après l’achèvement du processus de Regroupement d’Actions, les actions existantes de la Société seront annulées et ne seront plus en circulation. | (d) | Cancellation of existing shares: Following the completion of the Share Consolidation, the existing shares of the Company shall be cancelled and will no longer remain outstanding. | ||
| (e) | Calendrier du Regroupement d’Actions : Le conseil d’administration est autorisé à déterminer le Ratio définitif ainsi que la date effective du Regroupement d’Actions, à condition toutefois que le Regroupement d’Actions soit mis en œuvre au plus tard dans un délai de six mois à compter de la date de la présente assemblée générale extraordinaire des actionnaires. Le conseil d’administration a le pouvoir de ne pas procéder à la mise en œuvre du Regroupement d’Actions ou, dans le cas où la mise en œuvre du Regroupement d’Actions a déjà commencé, de suspendre ou d’annuler le processus de Regroupement d’Actions si le conseil d’administration détermine que les circonstances du marché ne permettent pas de réaliser le Regroupement d’Actions dans des conditions jugées satisfaisantes par le conseil d’administration. | (e) | Timing of the Share Consolidation: The board of directors shall be authorized to determine the final Ratio and the effective date of the Share Consolidation, provided however, that the Share Consolidation is to be implemented within a six-month period following the date of this extraordinary general shareholders’ meeting at the latest. The board of directors shall have the authority not to proceed with the implementation of the Share Consolidation, or, in case the implementation of the Share Consolidation has already started, to suspend or cancel the completion of the Share Consolidation if the board of directors determines that the market circumstances do not allow for the completion of the Share Consolidation in circumstances deemed satisfactory to it. | ||
| (f) | Agents : Une ou plusieurs banques ou institutions financières seront ou pourront être désignées par la Société aux fins de l’organisation et de la mise en œuvre du Regroupement d’Actions, en ce qui concerne respectivement les Actions Européennes et les Actions Américaines, y compris (mais sans s’y limiter) le regroupement des positions des Actions Européennes existantes et des Actions Américaines existantes qui ne peuvent être regroupées en un nombre entier de nouvelles actions conformément au Ratio, et la vente de nouvelles Actions Européennes et/ou de nouvelles Actions Américaines, selon le cas, comme le permet le paragraphe (c). | (f) | Agents: One or more banks or financial institutions shall or may be appointed by the Company for the purpose of the further organization and implementation of the Share Consolidation in relation to the European Shares and U.S. Shares, respectively, including (but not limited to) the consolidation of positions of existing European Shares and U.S. Shares, respectively, that cannot be consolidated into a whole number of new shares in accordance with the Ratio, and the sale of new European Shares and/or U.S. Shares, respectively, as permitted by paragraph (c). | ||
| (g) | Ajustement du prix de souscription des Droits de Souscription : À l’issue du Regroupement d’Actions, le Regroupement d’Actions sera effectué en ce qui concerne les droits de souscription en circulation de la Société de la manière envisagée dans les conditions respectives de ces droits de souscription, de sorte qu’un détenteur de droits de souscription devra exercer des droits de souscription à l’égard d’au moins un nombre d’actions avant le Regroupement d’Actions tel qu’exigé conformément au Ratio afin de pouvoir souscrire une ou plusieurs actions entières après le Regroupement d’Actions. | (g) | Adjustment of the subscription price of the Subscription Rights: At completion of the Share Consolidation, the Share Consolidation shall be effected in relation to the outstanding subscription rights of the Company in the manner as contemplated in the respective terms and conditions of these subscription rights, so that a holder of subscription rights will have to exercise subscription rights with respect to at least such number of shares prior to the Share Consolidation as shall be required in accordance with the Ratio in order to subscribe for one or more whole shares after the Share Consolidation |
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 7/10 |
| (h) | Modification des statuts : À l’issue du Regroupement d’Actions, l’article 5 des statuts de la Société sera modifié et reformulé pour tenir compte du nombre d’actions en circulation et existantes qui en résultera. | (h) | Amendment of the articles of association: At completion of the Share Consolidation, Article 5 of the Company’s articles of association shall be amended and restated to take into account the resulting number of outstanding and existing shares. | ||
| (i) | Mise en œuvre du Regroupement d’Actions : Sous réserve des règles applicables en matière de droit des sociétés, de droit financier et de droit des valeurs mobilières, et sous réserve des dispositions des paragraphes précédents, le conseil d’administration a le pouvoir de mettre en œuvre et d’exécuter le Regroupement d’Actions, y compris (sans s’y limiter) le pouvoir (i) de déterminer le Ratio définitif du Regroupement d’Actions, (ii) de déterminer la mise en œuvre pratique du Regroupement d’Actions (étant entendu qu’une mise en œuvre pratique différente peut être déterminée pour les actions inscrites dans la composante du registre des actions de la Société qui est tenue en Belgique et les actions inscrites directement ou indirectement dans la composante du registre des actions de la Société tenue aux États-Unis, sous réserve de ce qui est prévu au paragraphe (c) ci-dessus), (iii) de déterminer le calendrier et la date effective du Regroupement d’Actions comme prévu au paragraphe (e), (iv) de déterminer la manière et le processus de traitement des positions d’Actions Européennes existantes et d’Actions Américaines existantes qui ne peuvent pas être regroupées en un nombre entier de nouvelles actions conformément au Ratio comme prévu au paragraphe (c), (v) de nommer une ou plusieurs banques ou institutions financières pour l’organisation et la mise en œuvre du Regroupement d’Actions tel qu’envisagé au paragraphe (f), (vi) de procéder à la constatation de la modification et de la reformulation des statuts tels qu’envisagés au paragraphe (h) devant notaire, (vii) d’entreprendre toutes les démarches utiles ou nécessaires auprès de Nasdaq, d’Euroclear, de Computershare, de Depository Trust & Clearing Corporation et de toute autre agence de règlement compétente et de toute autorité de réglementation ou de cotation en rapport avec la mise en œuvre du Regroupement d’Actions, (viii) d’effectuer toutes les modifications dans les registres de titres pertinents de la Société reflétant le Regroupement d’Actions, et (ix) de prendre toutes les autres mesures utiles, appropriées ou nécessaires en rapport avec ce qui précède. Le conseil d’administration est habilité à déléguer la mise en œuvre et l’exécution du Regroupement d’Actions (y compris les pouvoirs visés aux points (i) à (ix)), en tout ou en partie, à un ou plusieurs membres du management ou du personnel de la Société. Tout administrateur, tout membre du management et toute autre personne expressément désignée à cet effet par le conseil d’administration est autorisé à faire constater, devant notaire, le Ratio définitif du Regroupement d’Actions ainsi que la modification et la reformulation des statuts visées au paragraphe (h). | (i) | Further implementation of the Share Consolidation: Subject to applicable company, financial and securities law rules, and subject to the provisions of the foregoing paragraphs, the board of directors shall have the authority to further implement and effect the Share Consolidation, including (without being limited to) the authority to (i) determine the final Ratio of the Share Consolidation, (ii) determine the practical implementation of the Share Consolidation (it being understood that a different practical implementation can be determined for the shares that are reflected in the component of the Company’s share register that is held in Belgium and the shares that are reflected directly or indirectly in the component of the Company’s share register that is held in the United States, subject to what is stated in paragraph (c) above), (iii) determine the timing and the effective date of the Share Consolidation as contemplated by paragraph (e), (iv) determine the manner and process to deal with positions of existing European Shares and U.S. Shares, respectively, that cannot be consolidated into a whole number of new shares in accordance with the Ratio as contemplated by paragraph (c), (v) appoint one or more banks or financial institutions for the further organization and implementation of the Share Consolidation as contemplated by paragraph (f), (vi) proceed with the recording of the amendment and the restatement of the articles of association as contemplated by paragraph (h) before a notary public, (vii) take all useful or necessary steps with Nasdaq, Euroclear, Computershare, Depository Trust & Clearing Corporation and any other competent settlement agency, and any regulatory or listing authority in connection with the implementation of the Share Consolidation, (viii) make all changes in the relevant securities register books of the Company reflecting the Share Consolidation, and (ix) do such other things as shall be useful, appropriate or necessary in connection with the foregoing. The board of directors shall have the authority to delegate the further implementation and execution of the Share Consolidation (including the powers referred to in sub-sections (i) to (ix)), in whole or in part, to one or more members of the Company’s executive management or personnel. Any director, any member of the executive management, and any other persons that shall be expressly appointed for such purpose by the board of directors shall be authorized to record the final Ratio of the Share Consolidation and the amendment and the restatement of the articles of association as contemplated by paragraph (h) before a notary public. |
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 8/10 |
| ► Instruction de vote: | ► Voting instruction: | |
| 0 Pour / For | 0 Contre / Against | 0 Abstention |
| II. Si l’assemblée générale extraordinaire des actionnaires est ajournée, prorogée ou suspendue, le mandataire spécial aura les pouvoirs de représenter le soussigné à l’assemblée générale des actionnaires qui sera tenue avec le même ordre du jour, le cas échéant (étant entendu que le vote susmentionné s’appliquera en tout état de cause également à la deuxième assemblée générale extraordinaire des actionnaires qui serait convoquée avec un ordre du jour identique à celui de la première assemblée générale extraordinaire des actionnaires dans le cas où le quorum de présence légalement requis pour délibérer et voter valablement sur ce point de l’ordre du jour n’aurait pas été atteint lors de la première assemblée générale extraordinaire des actionnaires): | II. In case the aforementioned extraordinary general shareholders’ meeting would be postponed, adjourned or suspended, the special proxy holder shall have the power to represent the undersigned at the general shareholders’ meeting that would be held having the same agenda, as relevant (it being understood that the aforementioned vote will in any event also apply to the second extraordinary general shareholders’ meeting which would be convened with an agenda identical to the agenda of the first extraordinary general shareholders’ meeting in case the legally required attendance quorum to validly deliberate and resolve on such agenda item would not be reached during the first extraordinary general shareholders’ meeting): |
| ☐ oui | ☐ yes |
| ☐ non | ☐ no |
| Veuillez remplir la case appropriée. Une absence d’instruction ou si, pour quelque raison, il y a une absence de clarté à propos de l’instruction donnée, le soussigné sera supposé avoir choisi “oui”. Veuillez noter qu’aux fins de s’appliquer à telle assemblée subséquente, les titulaires de titres doivent s’enregistrer à nouveau pour cette assemblée. | Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the undersigned shall be deemed to have selected “yes”. Please note that in order to apply for such subsequent meeting, holders of securities must again register for such meeting. |
| Si, pendant l’assemblée, il y a des modifications à la proposition de résolution ou une nouvelle proposition de résolution :1 | In case of amendments during the meeting to the proposed resolution or a new proposed resolution:1 |
| ☐ le mandataire spécial votera pour la résolution modifiée ou nouvelle | ☐ the proxy holder shall vote for the amended or new resolution |
| ☐ le mandataire spécial votera contre la résolution modifiée ou nouvelle | ☐ the proxy holder shall vote against the amended or new resolution |
| ☐ le mandataire spécial s’abstiendra de voter sur la résolution modifiée ou nouvelle | ☐ the proxy holder shall abstain from the vote on the amended or new resolution |
| ☐ le mandataire spécial votera sur la résolution modifiée ou nouvelle selon la manière supportée ou recommandée par le conseil d’administration de la Société | ☐ the proxy holder shall vote on the amended or new resolution in the manner supported or recommended by the board of directors of the Company |
| 1 Veuillez cocher tel qu’approprié. Une absence d’instruction sera interprétée comme une instruction de voter pour la résolution modifiée ou nouvelle selon la manière supportée ou recommandée par le conseil d’administration de la Société. | 1 Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended or new resolution as will be supported or recommended by the board of directors of the Company. |
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 9/10 |
| III. Le mandataire spécial est autorisé, au nom et pour le compte du soussigné, à signer la liste de présence et le procès-verbal, à participer à toutes les délibérations, à prendre part au vote sur la décision ou sujet pouvant, conformément à cet ordre du jour, être soumis à l’assemblée. | III. The special proxy holder has the power to, in the name of and on behalf of the undersigned, sign the attendance list and minutes, participate in the deliberations, vote with respect to the decision or item that can, pursuant to this agenda, be presented to said meeting. |
| IV. Le mandataire spécial est autorisé, en général, à faire tout ce qui semble nécessaire et/ou utile pour exercer cette procuration. | IV. In general, the special proxy holder has the power to do all that appears necessary and/or useful for the exercise of this proxy. |
| Le/la soussigné(e) ratifie et approuve par la présente tous les actes accomplis par le mandataire spécial susmentionné. Le mandataire spécial votera pour le compte du/de la soussigné(s) conformément aux instructions spécifiques données ci-dessus. | The undersigned hereby ratifies and approves all acts carried out by the aforementioned proxy holder. The special proxy holder will vote on behalf of the undersigned in accordance with the specific instructions given above. |
| La présente procuration vaut également notification conformément aux formalités décrites dans l’invitation à l’assemblée générale extraordinaire des actionnaires de la Société à tenir le jeudi 19 novembre 2026, à condition qu’elle soit dûment complétée par le soussigné et reçue par la Société au plus tard à la Date limite de Notification. | The present proxy shall also serve as notification in accordance with the formalities described in the notice convening the extraordinary general shareholders’ meeting of the Company to be held on Thursday, November 19, 2026, provided it is duly completed by the undersigned and received by the Company at the latest on the Notification Deadline. |
| Le soussigné confirme que la traduction anglaise de la présente procuration n’est qu’une traduction libre en anglais et à titre informatif uniquement, et que la version française prévaut sur la version anglaise. | The undersigned confirms that the English translation of the present proxy is a free English translation and for information purposes only, and that the French version shall prevail over the English version. |
| BON POUR PROCURATION | GOOD FOR PROXY |
| __________________ 2026 | ||
| (date) | ||
| (nom / name) | ||
| (signature) | ||
| Assemblée Générale Extraordinaire des Actionnaires de MDxHealth SA - Procuration | |
| Extraordinary General Shareholders’ Meeting of MDxHealth SA - Proxy | 10/10 |